SCHEMBL1149971

SCHEMBL1149971

CCOc1cnc(C#C[Si](C)(C)C)c(N)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
NPC1 O15118 2/20 0.35
APOBEC3G Q9HC16 1/20 0.35
MAPT P10636 5/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 3/20 0.34
TSHR P16473 2/20 0.34
TP53 P04637 2/20 0.34
CYP3A4 P08684 2/20 0.34
HSD17B10 Q99714 3/20 0.32
KDM4E B2RXH2 2/20 0.32
NQO1 P15559 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13772513 0.84 PIK3CA (0.33) ALDH1A1HSD17B10
SCHEMBL1150077 0.76 NOS3 (0.41) MAPTALDH1A1LMNATDP1TP53
SCHEMBL15055583 0.73
SCHEMBL17883465 0.73 IDO1 (0.35) CYP3A4
SCHEMBL14299582 0.71 GRM5 (0.43) NQO1
SCHEMBL4480451 0.70 PIK3CD (0.43) MEN1KMT2ANPC1TP53RAB9A
SCHEMBL1149974 0.69 MAPT (0.44) MEN1KMT2ANPC1APOBEC3GMAPT
SCHEMBL11828445 0.69 TDP1 (0.41) MEN1KMT2ANPC1APOBEC3GMAPT
SCHEMBL9113527 0.69 ACACB (0.44) MEN1KMT2ANPC1ALDH1A1TDP1
SCHEMBL5925863 0.69 ALDH1A1 (0.46) NPC1ALDH1A1LMNAHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580813-B2 Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI (FR) 2013-11-12 US disclosed
EP-2240482-B1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-07-17 EP disclosed
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-02-17 US disclosed
EP-2240482-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-10-20 EP disclosed
WO-2009095162-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, PM20D2, CDK20 MEN1 1406/4885KMT2A 1559/4885NPC1 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.